ClinicalTrials.gg
CompletedNCT04976192Updated Oct 7, 2025Results posted

Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

A Phase 3 interventional study of TEV-45779 and XOLAIR® Injection in Chronic Urticaria, sponsored by Teva Pharmaceuticals USA. Completed at 9 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-07.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
608
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Chronic Urticaria with a site in United States — 9 open to participants now, 16 under way, 6 of them phase 3. Chronic Urticaria · United States.

Enrollment
8th of 58
608 · median 132
Started
2021
with 3 others
Phase 3
21 of 64
1 open now
Registered
32nd of 64
by date

Among the 64 studies in Chronic Urticaria with a site in United States, this one is the 8th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2021, is one of 21 in phase 3, and was the 32nd registered.

Chronic Urticaria

199 studies on the registry are indexed under Chronic Urticaria; 51 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

9 of the 64 studies in Chronic Urticaria with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Chronic Urticaria with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to compare the efficacy, pharmacokinetics, pharmacodynamics, safety, tolerability, and immunogenicity of TEV-45779 compared to XOLAIR in patients with Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) who remain symptomatic on H1 antihistamine treatment.

Read the detailed description

This is a multicenter, randomized, double-blind study to demonstrate similar efficacy and safety of TEV-45779 compared to XOLAIR administered sc at doses of 300 mg or 150 mg every 4 weeks for 24 weeks (6 treatments) in patients with Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) who remain symptomatic despite antihistamine (H1) treatment. This study will consist of a screening period (up to 2 weeks), a 24-week treatment period consisting of a 12-week double-blind main treatment period and a 12-week double-blind transition period, which is followed by a 16-week follow-up period. The total duration of the study is up to 42 weeks.

At baseline, patients will be randomized in a 2:2:1:1 ratio to receive the first 3 treatments of TEV-45779 300 mg, XOLAIR 300 mg, TEV-45779 150 mg or XOLAIR 150 mg (main treatment period). At Week 12, prior to receiving their fourth dose of study medication, patients in the XOLAIR 300 mg and the XOLAIR 150 mg treatment groups will be randomized 1:1 to receive 3 additional doses of XOLAIR (at the same dose level as prior to randomization, or switch to 3 doses of TEV-45779 (transition period) at the same dose level as prior to randomization. All patients in the TEV-45779 groups will continue to receive TEV-45779 at the same dose levels.

03

Conditions studied

  • Chronic Urticaria

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of CIU to H1 antihistamines for ≥3 months

Exclusion criteria

Exclusion Criteria:

  • Chronic urticaria with clearly defined underlying etiology
  • Other skin disease associated with itch
  • Evidence of parasitic infection on stool evaluation for ova and parasites
  • History of anaphylactic shock
  • to omalizumab or any component of the formulation
  • Required background therapy with other than protocol-defined antihistamines
  • Any medical condition that could jeopardize or would compromise the patient's safety or ability to participate in this study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
608 participants (actual)

Study arms

  • Experimental
    TEV-45779-300 mg Main Treatment period

    TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8

    Combination Product: TEV-45779

  • Active comparator
    Xolair-300 mg Main Treatment Period

    XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8

    Combination Product: XOLAIR® Injection

  • Experimental
    TEV-45779-150 mg Main Treatment period

    TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8

    Combination Product: TEV-45779

  • Active comparator
    Xolair-150 mg Main Treatment Period

    XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8

    Combination Product: XOLAIR® Injection

  • Experimental
    TEV-45779-300 mg Main / TEV45779-300 mg Transition Period

    TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to TEV-45779-300 mg in the Main Treatment period.

    Combination Product: TEV-45779

  • Experimental
    Xolair-300 mg Main / TEV45779-300 mg Transition Period

    TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.

    Combination Product: TEV-45779 · Combination Product: XOLAIR® Injection

  • Active comparator
    Xolair-300 mg Main / Xolair-300 mg Transition Period

    XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.

    Combination Product: XOLAIR® Injection

  • Experimental
    TEV-45779-150 mg Main / TEV-45779-150 mg Transition Period

    TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to TEV-45779-150 mg in the main treatment period.

    Combination Product: TEV-45779

  • Experimental
    Xolair-150 mg Main / TEV-45779-150 mg Transition Period

    TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR-150 mg in the main treatment period.

    Combination Product: TEV-45779 · Combination Product: XOLAIR® Injection

  • Active comparator
    Xolair-150 mg Main / Xolair-150 mg Transition Period

    XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR -150 mg in the main treatment period.

    Combination Product: XOLAIR® Injection

Interventions

  • Combination productTEV-45779

    TEV-45779 (Omalizumab) solution for injection 150 mg/mL prefilled syringe

  • Combination productOmalizumabStudies of OmalizumabOmalizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the ISS7 at Week 12, TEV-45779 High Dose Compared to XOLAIR High Dose (For European Medicines Agency [EMA] Submission)

    The severity of the itch was recorded by the participants twice daily in their eDiary, on a scale of 0 (none) to 3 (intense/severe). A weekly itch score (ISS7) was defined as the sum of the available daily itch severity scores in that week, divided by the number of days for which a daily itch severity score was available, multiplied by 7. The daily ISS was calculated as the average of the morning and evening scores. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severe itching. Least square (LS) mean and 95% confidence interval (CI) were calculated using analysis of covariance (ANCOVA) model. Multiple imputation performed both for the participants having missing ISS7 at week 12 and for participants using any disallowed concomitant medication.

    Time frame: Baseline, Week 12

  2. Change From Baseline in the ISS7 at Week 12, TEV-45779 High Dose Compared to XOLAIR High Dose (For Food and Drug Administration [FDA] Submission)

    The severity of the itch was recorded by the participants twice daily in their eDiary, on a scale of 0 (none) to 3 (intense/severe). A weekly itch score (ISS7) was defined as the sum of the available daily itch severity scores in that week, divided by the number of days for which a daily itch severity score was available, multiplied by 7. The daily ISS was calculated as the average of the morning and evening scores. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severe itching. LS mean and 90% CI were calculated using ANCOVA model. Multiple imputation performed for the participants having missing ISS7 at week 12.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in the ISS7 at Weeks 4 and 12

    The severity of the itch was recorded by the participants twice daily in their eDiary, on a scale of 0 (none) to 3 (intense/severe). A weekly itch score (ISS7) was defined as the sum of the available daily itch severity scores in that week, divided by the number of days for which a daily itch severity score was available, multiplied by 7. The daily ISS was calculated as the average of the morning and evening scores. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severe itching. The observed mean and standard deviation values are reported here with no imputation performed.

    Time frame: Baseline, Weeks 4 and 12

  2. Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12

    The UAS was a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0 - 3 (0 = none to 3 = intense/severe) for (1) the number of wheals (hives); and (2) the intensity of the itch separately, measured twice daily (morning and evening). The daily UAS was the average of the morning and evening scores, which ranged from 0 (none) to 6 (severe). The UAS7 was the sum of the daily UAS scores over 7 days, which ranged from 0 (minimum) to 42 (highest urticaria severity). Higher scores indicated greater severity of urticaria symptoms.

    Time frame: Baseline, Week 12

  3. Percentage of Participants With a UAS7 Score ≤6 at Week 12

    The UAS was a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0 - 3 (0 = none to 3 = intense/severe) for (1) the number of wheals (hives); and (2) the intensity of the itch separately, measured twice daily (morning and evening). The daily UAS was the average of the morning and evening scores, which ranged from 0 (none) to 6 (severe). The UAS7 is the number of participants achieving the endpoint of less than or equal to 6. UAS7 was calculated as the sum of the daily UAS scores over 7 days, which ranged from 0 (minimum) to 42 (highest urticaria severity). Higher scores indicated greater severity of urticaria symptoms.

    Time frame: Week 12

  4. Percentage of Complete Responders (UAS7 Score = 0) at Week 12

    The UAS was a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0 - 3 (0 = none to 3 = intense/severe) for (1) the number of wheals (hives); and (2) the intensity of the itch separately, measured twice daily (morning and evening). The daily UAS was the average of the morning and evening scores, which ranged from 0 (none) to 6 (severe). The UAS7 was the sum of the daily UAS scores over 7 days, which ranged from 0 (minimum) to 42 (highest urticaria severity). Higher scores indicated greater severity of urticaria symptoms. Complete responders were participants with a UAS7 score = 0.

    Time frame: Week 12

  5. Change From Baseline in the Physician's (In-clinic) Assessment of UAS at Week 12

    Physician's (in-clinic) assessment of UAS score was performed using the in-clinic UAS. The physician, or the person designated, provided the sum of the score of the participant's urticaria lesions (number of wheals \[hives\]) and pruritus (itch) reflective of the participant's condition over the 12 hours prior to the visit using the rating scale of 0 - 6 (0 = none to 6 = intense/severe). Higher scores indicated greater severity of urticaria symptoms.

    Time frame: Baseline, Week 12

  6. Change From Baseline in the Weekly Number of Wheals Score at Week 12

    The wheals (hives) severity score, defined by number of wheals (hives), was recorded by the participant twice daily in their eDiary, on a scale of 0 (none) to 3 (\> 12 hives/12 hours). A weekly number of wheals score was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 (no wheals) - 21 (highest hives activity).

    Time frame: Baseline, Week 12

  7. Change From Baseline in the Weekly Size of the Largest Wheals Score at Week 12

    The weekly size of the largest wheals score was calculated from the eDiary data. A wheal score of 0 was assigned when \<10 small wheals (diameter \<3 centimeters \[cm\]) were present, presence of 10-50 small wheals or less than 10 large wheals (diameter \>3 cm) was denoted by score of 1. A score of 2 was assigned when more than 50 small wheals or 10 to 50 large wheals were present. A score of 3 denoted wheals covering almost the entire body surface area. A weekly score was defined as the sum of the available daily size of the largest wheals scores in that week, divided by the number of days for which a daily score was available, multiplied by 7. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severity.

    Time frame: Baseline, Week 12

  8. Time to Minimally Important Difference (MID) Response in ISS7 Score

    Time to MID response was defined as time to a reduction from baseline in ISS7 of ≥5 points in ISS7 score by Week 12.

    Time frame: Baseline up to Week 12

  9. Percentage of ISS7 MID Responders at Week 12

    A responder was defined as a participant with a reduction from baseline in ISS7 of ≥5 points in ISS7 score.

    Time frame: Week 12

  10. Percentage of Angioedema-Free Days From Week 4 to Week 12

    Percentage of angioedema-free days from Week 4 to Week 12 were calculated based on the diary data as the number of days in the diary between the dates of Week 4 and Week 12 visits with no angioedema episodes, divided by the total number of days with diary entries in this time span \* 100%.

    Time frame: Week 4 to Week 12

  11. Change From Baseline in the Overall Dermatology Life Quality Index (DLQI) Score at Week 12

    The DLQI consisted of 10 questions concerning participants' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. The DLQI total score was calculated by adding the score of each question (scored as follows: Very much = 3; Yes \[in question 7.a\] = 3; A lot = 2; A little = 1; Not at all = 0; Not relevant = 0; No \[in question 7.a\] = 0; Question unanswered = 0), resulting in a maximum of 30 and a minimum of 0. The higher the score, the more the quality of life was impaired. A score higher than 10 indicated that the participant's life was being severely affected by their skin disease.

    Time frame: Baseline, Week 12

  12. Change From Week 12 in ISS7 at Weeks 24 and 40

    The severity of the itch was recorded by the participants twice daily in their eDiary, on a scale of 0 (none) to 3 (intense/severe). A weekly itch score (ISS7) was defined as the sum of the available daily itch severity scores in that week, divided by the number of days for which a daily itch severity score was available, multiplied by 7. The daily ISS was calculated as the average of the morning and evening scores. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severe itching.

    Time frame: Week 12, Weeks 24 and 40

  13. Change From Week 12 in the UAS7 at Week 24

    The UAS was a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0 - 3 (0 = none to 3 = intense/severe) for (1) the number of wheals (hives); and (2) the intensity of the itch separately, measured twice daily (morning and evening). The daily UAS was the average of the morning and evening scores, which can range from 0 (none) to 6 (severe). The UAS7 was the sum of the daily UAS scores over 7 days, which can range from 0 (minimum) to 42 (highest urticaria severity). Higher scores indicated greater severity of urticaria symptoms.

    Time frame: Week 12, Week 24

  14. Change From Week 12 in the Physician's (In-clinic) Assessment of UAS7 at Week 24

    Physician's (in-clinic) assessment of UAS score was performed using the in-clinic UAS. The physician, or the person designated, provided the sum of the score of the participant's urticaria lesions (number of wheals \[hives\]) and pruritus (itch) reflective of the participant's condition over the 12 hours prior to the visit using the rating scale of 0 - 6 (0 = none to 6 = intense/severe). Higher scores indicated greater severity of urticaria symptoms.

    Time frame: Week 12, Week 24

  15. Change From Week 12 in the Weekly Number of Wheals Score at Weeks 24 and 40

    The wheals (hives) severity score, defined by number of wheals (hives), was recorded by the participant twice daily in their eDiary, on a scale of 0 (none) to 3 (\> 12 hives/12 hours). A weekly number of wheals score was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 (no wheals) - 21 (highest hives activity).

    Time frame: Week 12, Weeks 24 and 40

  16. Change From Week 12 in the Weekly Size of the Largest Wheals Score at Weeks 24 and 40

    The weekly size of the largest wheals score was calculated from eDiary data. A wheal score of 0 was assigned when \<10 small wheals (diameter \<3 cm) were present, presence of 10-50 small wheals or less than 10 large wheals (diameter \>3 cm) was denoted by score 1. A score of 2 was assigned when more than 50 small wheals or 10 to 50 large wheals were present. A score of 3 denoted wheals covering almost the entire body surface area. A weekly score was defined as sum of available daily size of the largest wheals scores in that week, divided by the number of days for which a daily score was available, multiplied by 7. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severity.

    Time frame: Week 12, Weeks 24 and 40

  17. Percentage of Angioedema-Free Days From Week 12 to Week 24

    Percentage of angioedema-free days from Week 12 to Week 24 was calculated based on the diary data as the number of days in the diary between the dates of Week 12 and Week 24 visits with no angioedema episodes, divided by the total number of days with diary entries in this time span \* 100%.

    Time frame: Week 12 to Week 24

  18. Change From Week 12 in the Overall DLQI Score at Weeks 24 and 40

    The DLQI consisted of 10 questions concerning participants' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. The DLQI total score was calculated by adding the score of each question (scored as follows: Very much = 3; Yes \[in question 7.a\] = 3; A lot = 2; A little = 1; Not at all = 0; Not relevant = 0; No \[in question 7.a\] = 0; Question unanswered = 0), resulting in a maximum of 30 and a minimum of 0. The higher the score, the more the quality of life was impaired. A score higher than 10 indicated that the participant's life was being severely affected by their skin disease.

    Time frame: Week 12, Weeks 24 and 40

  19. Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) in the Main Treatment Period

    An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious AEs (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. AEs were considered TEAEs if onset occurred or worsened on or after the first dose date. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Baseline up to Week 12

  20. Number of Participants With at Least One TEAE Week 12 up to Week 24

    An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. AEs were considered TEAEs if onset occurred or worsened on or after the first dose date. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Week 12 up to Week 24

  21. Number of Participants With Antidrug Antibodies (ADAs) in the Main Treatment Period

    Number of participants with positive ADA, positive ADA not treatment-related, and negative ADA are reported.

    Time frame: Baseline up to Week 12

  22. Number of Participants With ADAs From Week 12 to Week 24

    Number of participants with positive ADA, positive ADA not treatment-related, and negative ADA are reported.

    Time frame: Week 12 up to Week 24

07

Results

Posted Oct 7, 2025

Participant flow

Main Treatment Period (12 Weeks)
Participant flow — Main Treatment Period (12 Weeks)
MilestoneMain Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low DoseTransition Period: TEV-45779/TEV-45779 High DoseTransition Period: TEV-45779/TEV-45779 Low DoseTransition Period: XOLAIR/XOLAIR High DoseTransition Period: XOLAIR/XOLAIR Low DoseTransition Period: XOLAIR/TEV-45779 High DoseTransition Period: XOLAIR/TEV-45779 Low Dose
Started201102203102000000
Received at least 1 dose of study drug201102203102000000
Completed18898194101000000
Not completed13491000000
Withdrew: Adverse event0100000000
Withdrew: Withdrawal by subject12381000000
Withdrew: Other than specified1010000000
Transition Treatment Period (12 Weeks)
Participant flow — Transition Treatment Period (12 Weeks)
MilestoneMain Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low DoseTransition Period: TEV-45779/TEV-45779 High DoseTransition Period: TEV-45779/TEV-45779 Low DoseTransition Period: XOLAIR/XOLAIR High DoseTransition Period: XOLAIR/XOLAIR Low DoseTransition Period: XOLAIR/TEV-45779 High DoseTransition Period: XOLAIR/TEV-45779 Low Dose
Started00001889897519750
Received at least 1 dose of study drug00001889897519750
Completed00001789093499547
Not completed00001084223
Withdrew: Withdrawal by subject0000974223
Withdrew: Other than specified0000100000
Withdrew: Lost to follow-up0000010000

Outcome measures

PrimaryChange From Baseline in the ISS7 at Week 12, TEV-45779 High Dose Compared to XOLAIR High Dose (For European Medicines Agency [EMA] Submission)

The severity of the itch was recorded by the participants twice daily in their eDiary, on a scale of 0 (none) to 3 (intense/severe). A weekly itch score (ISS7) was defined as the sum of the available daily itch severity scores in that week, divided by the number of days for which a daily itch severity score was available, multiplied by 7. The daily ISS was calculated as the average of the morning and evening scores. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severe itching. Least square (LS) mean and 95% confidence interval (CI) were calculated using analysis of covariance (ANCOVA) model. Multiple imputation performed both for the participants having missing ISS7 at week 12 and for participants using any disallowed concomitant medication.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the ISS7 at Week 12, TEV-45779 High Dose Compared to XOLAIR High Dose (For European Medicines Agency [EMA] Submission)
units on a scaleMain Treatment Period: TEV-45779 High DoseMain Treatment Period: XOLAIR High Dose
Change From Baseline in the ISS7 at Week 12, TEV-45779 High Dose Compared to XOLAIR High Dose (For European Medicines Agency [EMA] Submission)-10.92 ± -11.85-10.61 ± -11.51
Statistical analysis
  • Main Treatment Period: TEV-45779 High Dose vs Main Treatment Period: XOLAIR High Dose · Ls mean difference: -0.31 · 95% CI -1.56 to 0.94
PrimaryChange From Baseline in the ISS7 at Week 12, TEV-45779 High Dose Compared to XOLAIR High Dose (For Food and Drug Administration [FDA] Submission)

The severity of the itch was recorded by the participants twice daily in their eDiary, on a scale of 0 (none) to 3 (intense/severe). A weekly itch score (ISS7) was defined as the sum of the available daily itch severity scores in that week, divided by the number of days for which a daily itch severity score was available, multiplied by 7. The daily ISS was calculated as the average of the morning and evening scores. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severe itching. LS mean and 90% CI were calculated using ANCOVA model. Multiple imputation performed for the participants having missing ISS7 at week 12.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the ISS7 at Week 12, TEV-45779 High Dose Compared to XOLAIR High Dose (For Food and Drug Administration [FDA] Submission)
units on a scaleMain Treatment Period: TEV-45779 High DoseMain Treatment Period: XOLAIR High Dose
Change From Baseline in the ISS7 at Week 12, TEV-45779 High Dose Compared to XOLAIR High Dose (For Food and Drug Administration [FDA] Submission)-10.77 (-11.61 to -9.93)-10.38 (-11.24 to -9.52)
Statistical analysis
  • Main Treatment Period: TEV-45779 High Dose vs Main Treatment Period: XOLAIR High Dose · Ls mean difference: -0.39 · 90% CI -1.37 to 0.58
  • Main Treatment Period: TEV-45779 High Dose vs Main Treatment Period: XOLAIR High Dose · Relative potency: 0.89Relative potency of TEV-45779 and XOLAIR is a co-primary efficacy endpoint for FDA submission.
SecondaryChange From Baseline in the ISS7 at Weeks 4 and 12

The severity of the itch was recorded by the participants twice daily in their eDiary, on a scale of 0 (none) to 3 (intense/severe). A weekly itch score (ISS7) was defined as the sum of the available daily itch severity scores in that week, divided by the number of days for which a daily itch severity score was available, multiplied by 7. The daily ISS was calculated as the average of the morning and evening scores. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severe itching. The observed mean and standard deviation values are reported here with no imputation performed.

Time frame:
Baseline, Weeks 4 and 12
Reported as:
Mean · units on a scale
Change From Baseline in the ISS7 at Weeks 4 and 12
units on a scaleMain Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low Dose
Change at Week 4-7.64 ± 6.383-7.35 ± 6.236-7.87 ± 6.033-7.27 ± 6.084
Change at Week 12-10.92 ± 6.512-9.96 ± 6.340-10.65 ± 6.490-10.35 ± 6.082
SecondaryChange From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12

The UAS was a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0 - 3 (0 = none to 3 = intense/severe) for (1) the number of wheals (hives); and (2) the intensity of the itch separately, measured twice daily (morning and evening). The daily UAS was the average of the morning and evening scores, which ranged from 0 (none) to 6 (severe). The UAS7 was the sum of the daily UAS scores over 7 days, which ranged from 0 (minimum) to 42 (highest urticaria severity). Higher scores indicated greater severity of urticaria symptoms.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12
units on a scaleMain Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low Dose
Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12-22.10 ± 13.204-20.67 ± 12.223-21.73 ± 12.651-21.67 ± 12.158
SecondaryPercentage of Participants With a UAS7 Score ≤6 at Week 12

The UAS was a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0 - 3 (0 = none to 3 = intense/severe) for (1) the number of wheals (hives); and (2) the intensity of the itch separately, measured twice daily (morning and evening). The daily UAS was the average of the morning and evening scores, which ranged from 0 (none) to 6 (severe). The UAS7 is the number of participants achieving the endpoint of less than or equal to 6. UAS7 was calculated as the sum of the daily UAS scores over 7 days, which ranged from 0 (minimum) to 42 (highest urticaria severity). Higher scores indicated greater severity of urticaria symptoms.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a UAS7 Score ≤6 at Week 12
percentage of participantsMain Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low Dose
Percentage of Participants With a UAS7 Score ≤6 at Week 1249.545.846.448.5
SecondaryPercentage of Complete Responders (UAS7 Score = 0) at Week 12

The UAS was a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0 - 3 (0 = none to 3 = intense/severe) for (1) the number of wheals (hives); and (2) the intensity of the itch separately, measured twice daily (morning and evening). The daily UAS was the average of the morning and evening scores, which ranged from 0 (none) to 6 (severe). The UAS7 was the sum of the daily UAS scores over 7 days, which ranged from 0 (minimum) to 42 (highest urticaria severity). Higher scores indicated greater severity of urticaria symptoms. Complete responders were participants with a UAS7 score = 0.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Complete Responders (UAS7 Score = 0) at Week 12
percentage of participantsMain Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low Dose
Percentage of Complete Responders (UAS7 Score = 0) at Week 1233.228.129.630.9
SecondaryChange From Baseline in the Physician's (In-clinic) Assessment of UAS at Week 12

Physician's (in-clinic) assessment of UAS score was performed using the in-clinic UAS. The physician, or the person designated, provided the sum of the score of the participant's urticaria lesions (number of wheals \[hives\]) and pruritus (itch) reflective of the participant's condition over the 12 hours prior to the visit using the rating scale of 0 - 6 (0 = none to 6 = intense/severe). Higher scores indicated greater severity of urticaria symptoms.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Physician's (In-clinic) Assessment of UAS at Week 12
units on a scaleMain Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low Dose
Change From Baseline in the Physician's (In-clinic) Assessment of UAS at Week 12-3.38 ± 2.002-3.34 ± 1.907-3.55 ± 1.893-3.15 ± 2.085
SecondaryChange From Baseline in the Weekly Number of Wheals Score at Week 12

The wheals (hives) severity score, defined by number of wheals (hives), was recorded by the participant twice daily in their eDiary, on a scale of 0 (none) to 3 (\> 12 hives/12 hours). A weekly number of wheals score was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 (no wheals) - 21 (highest hives activity).

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Weekly Number of Wheals Score at Week 12
units on a scaleMain Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low Dose
Change From Baseline in the Weekly Number of Wheals Score at Week 12-11.18 ± 7.127-10.70 ± 6.551-11.09 ± 6.740-11.33 ± 6.672
SecondaryChange From Baseline in the Weekly Size of the Largest Wheals Score at Week 12

The weekly size of the largest wheals score was calculated from the eDiary data. A wheal score of 0 was assigned when \<10 small wheals (diameter \<3 centimeters \[cm\]) were present, presence of 10-50 small wheals or less than 10 large wheals (diameter \>3 cm) was denoted by score of 1. A score of 2 was assigned when more than 50 small wheals or 10 to 50 large wheals were present. A score of 3 denoted wheals covering almost the entire body surface area. A weekly score was defined as the sum of the available daily size of the largest wheals scores in that week, divided by the number of days for which a daily score was available, multiplied by 7. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severity.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Weekly Size of the Largest Wheals Score at Week 12
units on a scaleMain Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low Dose
Change From Baseline in the Weekly Size of the Largest Wheals Score at Week 12-10.28 ± 6.937-9.52 ± 6.670-10.45 ± 6.745-10.68 ± 6.838
SecondaryTime to Minimally Important Difference (MID) Response in ISS7 Score

Time to MID response was defined as time to a reduction from baseline in ISS7 of ≥5 points in ISS7 score by Week 12.

Time frame:
Baseline up to Week 12
Reported as:
Median · weeks
Time to Minimally Important Difference (MID) Response in ISS7 Score
weeksMain Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low Dose
Time to Minimally Important Difference (MID) Response in ISS7 Score2.0 (2.0 to 3.0)2.0 (1.0 to 2.0)2.0 (NA to NA)2.0 (2.0 to 3.0)
SecondaryPercentage of ISS7 MID Responders at Week 12

A responder was defined as a participant with a reduction from baseline in ISS7 of ≥5 points in ISS7 score.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of ISS7 MID Responders at Week 12
percentage of participantsMain Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low Dose
Percentage of ISS7 MID Responders at Week 1281.078.180.679.4
SecondaryPercentage of Angioedema-Free Days From Week 4 to Week 12

Percentage of angioedema-free days from Week 4 to Week 12 were calculated based on the diary data as the number of days in the diary between the dates of Week 4 and Week 12 visits with no angioedema episodes, divided by the total number of days with diary entries in this time span \* 100%.

Time frame:
Week 4 to Week 12
Reported as:
Median · percentage of days
Percentage of Angioedema-Free Days From Week 4 to Week 12
percentage of daysMain Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low Dose
Percentage of Angioedema-Free Days From Week 4 to Week 12100.00 ± 0.0100.00 ± 0.0100.00 ± 0.0100.00 ± 0.0
SecondaryChange From Baseline in the Overall Dermatology Life Quality Index (DLQI) Score at Week 12

The DLQI consisted of 10 questions concerning participants' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. The DLQI total score was calculated by adding the score of each question (scored as follows: Very much = 3; Yes \[in question 7.a\] = 3; A lot = 2; A little = 1; Not at all = 0; Not relevant = 0; No \[in question 7.a\] = 0; Question unanswered = 0), resulting in a maximum of 30 and a minimum of 0. The higher the score, the more the quality of life was impaired. A score higher than 10 indicated that the participant's life was being severely affected by their skin disease.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Overall Dermatology Life Quality Index (DLQI) Score at Week 12
units on a scaleMain Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low Dose
Change From Baseline in the Overall Dermatology Life Quality Index (DLQI) Score at Week 12-9.72 ± 7.125-8.40 ± 7.28-9.54 ± 7.091-8.09 ± 6.432
SecondaryChange From Week 12 in ISS7 at Weeks 24 and 40

The severity of the itch was recorded by the participants twice daily in their eDiary, on a scale of 0 (none) to 3 (intense/severe). A weekly itch score (ISS7) was defined as the sum of the available daily itch severity scores in that week, divided by the number of days for which a daily itch severity score was available, multiplied by 7. The daily ISS was calculated as the average of the morning and evening scores. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severe itching.

Time frame:
Week 12, Weeks 24 and 40
Reported as:
Mean · units on a scale
Change From Week 12 in ISS7 at Weeks 24 and 40
units on a scaleTransition Period: TEV-45779/TEV-45779 High DoseTransition Period: TEV-45779/TEV-45779 Low DoseTransition Period: XOLAIR/XOLAIR High DoseTransition Period: XOLAIR/XOLAIR Low DoseTransition Period: XOLAIR/TEV-45779 High DoseTransition Period: XOLAIR/TEV-45779 Low Dose
Change at Week 24-1.64 ± 3.598-1.37 ± 4.576-1.82 ± 4.016-1.21 ± 3.186-1.78 ± 4.226-2.09 ± 4.585
Change at Week 401.84 ± 7.1820.44 ± 6.9821.43 ± 6.8701.58 ± 5.2742.03 ± 7.9691.27 ± 6.718
SecondaryChange From Week 12 in the UAS7 at Week 24

The UAS was a composite eDiary-recorded score with numeric severity intensity ratings on a scale of 0 - 3 (0 = none to 3 = intense/severe) for (1) the number of wheals (hives); and (2) the intensity of the itch separately, measured twice daily (morning and evening). The daily UAS was the average of the morning and evening scores, which can range from 0 (none) to 6 (severe). The UAS7 was the sum of the daily UAS scores over 7 days, which can range from 0 (minimum) to 42 (highest urticaria severity). Higher scores indicated greater severity of urticaria symptoms.

Time frame:
Week 12, Week 24
Reported as:
Mean · units on a scale
Change From Week 12 in the UAS7 at Week 24
units on a scaleTransition Period: TEV-45779/TEV-45779 High DoseTransition Period: TEV-45779/TEV-45779 Low DoseTransition Period: XOLAIR/XOLAIR High DoseTransition Period: XOLAIR/XOLAIR Low DoseTransition Period: XOLAIR/TEV-45779 High DoseTransition Period: XOLAIR/TEV-45779 Low Dose
Change From Week 12 in the UAS7 at Week 24-3.37 ± 6.641-2.66 ± 9.524-3.65 ± 7.953-2.54 ± 7.546-3.45 ± 8.387-3.12 ± 9.419
SecondaryChange From Week 12 in the Physician's (In-clinic) Assessment of UAS7 at Week 24

Physician's (in-clinic) assessment of UAS score was performed using the in-clinic UAS. The physician, or the person designated, provided the sum of the score of the participant's urticaria lesions (number of wheals \[hives\]) and pruritus (itch) reflective of the participant's condition over the 12 hours prior to the visit using the rating scale of 0 - 6 (0 = none to 6 = intense/severe). Higher scores indicated greater severity of urticaria symptoms.

Time frame:
Week 12, Week 24
Reported as:
Mean · units on a scale
Change From Week 12 in the Physician's (In-clinic) Assessment of UAS7 at Week 24
units on a scaleTransition Period: TEV-45779/TEV-45779 High DoseTransition Period: TEV-45779/TEV-45779 Low DoseTransition Period: XOLAIR/XOLAIR High DoseTransition Period: XOLAIR/XOLAIR Low DoseTransition Period: XOLAIR/TEV-45779 High DoseTransition Period: XOLAIR/TEV-45779 Low Dose
Change From Week 12 in the Physician's (In-clinic) Assessment of UAS7 at Week 24-0.55 ± 1.556-0.40 ± 2.032-0.27 ± 1.360-0.53 ± 1.838-0.38 ± 1.413-0.67 ± 1.548
SecondaryChange From Week 12 in the Weekly Number of Wheals Score at Weeks 24 and 40

The wheals (hives) severity score, defined by number of wheals (hives), was recorded by the participant twice daily in their eDiary, on a scale of 0 (none) to 3 (\> 12 hives/12 hours). A weekly number of wheals score was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 (no wheals) - 21 (highest hives activity).

Time frame:
Week 12, Weeks 24 and 40
Reported as:
Mean · units on a scale
Change From Week 12 in the Weekly Number of Wheals Score at Weeks 24 and 40
units on a scaleTransition Period: TEV-45779/TEV-45779 High DoseTransition Period: TEV-45779/TEV-45779 Low DoseTransition Period: XOLAIR/XOLAIR High DoseTransition Period: XOLAIR/XOLAIR Low DoseTransition Period: XOLAIR/TEV-45779 High DoseTransition Period: XOLAIR/TEV-45779 Low Dose
Change at Week 24-1.73 ± 3.649-1.29 ± 5.262-1.84 ± 4.139-1.33 ± 4.793-1.67 ± 4.510-1.03 ± 5.281
Change at Week 401.87 ± 7.4120.60 ± 8.2361.53 ± 6.9532.05 ± 6.1102.77 ± 8.6202.13 ± 7.809
SecondaryChange From Week 12 in the Weekly Size of the Largest Wheals Score at Weeks 24 and 40

The weekly size of the largest wheals score was calculated from eDiary data. A wheal score of 0 was assigned when \<10 small wheals (diameter \<3 cm) were present, presence of 10-50 small wheals or less than 10 large wheals (diameter \>3 cm) was denoted by score 1. A score of 2 was assigned when more than 50 small wheals or 10 to 50 large wheals were present. A score of 3 denoted wheals covering almost the entire body surface area. A weekly score was defined as sum of available daily size of the largest wheals scores in that week, divided by the number of days for which a daily score was available, multiplied by 7. The possible range of the weekly score was therefore 0 (best score) to 21 (worst score) with higher scores indicating more severity.

Time frame:
Week 12, Weeks 24 and 40
Reported as:
Mean · units on a scale
Change From Week 12 in the Weekly Size of the Largest Wheals Score at Weeks 24 and 40
units on a scaleTransition Period: TEV-45779/TEV-45779 High DoseTransition Period: TEV-45779/TEV-45779 Low DoseTransition Period: XOLAIR/XOLAIR High DoseTransition Period: XOLAIR/XOLAIR Low DoseTransition Period: XOLAIR/TEV-45779 High DoseTransition Period: XOLAIR/TEV-45779 Low Dose
Change at Week 24-1.87 ± 3.898-1.28 ± 4.697-1.78 ± 4.334-1.18 ± 4.464-1.94 ± 4.776-0.88 ± 4.456
Change at Week 401.46 ± 7.4340.72 ± 7.8991.34 ± 7.3322.35 ± 5.9682.71 ± 8.7061.87 ± 7.798
SecondaryPercentage of Angioedema-Free Days From Week 12 to Week 24

Percentage of angioedema-free days from Week 12 to Week 24 was calculated based on the diary data as the number of days in the diary between the dates of Week 12 and Week 24 visits with no angioedema episodes, divided by the total number of days with diary entries in this time span \* 100%.

Time frame:
Week 12 to Week 24
Reported as:
Median · percentage of days
Percentage of Angioedema-Free Days From Week 12 to Week 24
percentage of daysTransition Period: TEV-45779/TEV-45779 High DoseTransition Period: TEV-45779/TEV-45779 Low DoseTransition Period: XOLAIR/XOLAIR High DoseTransition Period: XOLAIR/XOLAIR Low DoseTransition Period: XOLAIR/TEV-45779 High DoseTransition Period: XOLAIR/TEV-45779 Low Dose
Percentage of Angioedema-Free Days From Week 12 to Week 24100.00 ± 0.0100.00 ± 0.0100.00 ± 0.0100.00 ± 0.0100.00 ± 0.0100.00 ± 0.0
SecondaryChange From Week 12 in the Overall DLQI Score at Weeks 24 and 40

The DLQI consisted of 10 questions concerning participants' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. The DLQI total score was calculated by adding the score of each question (scored as follows: Very much = 3; Yes \[in question 7.a\] = 3; A lot = 2; A little = 1; Not at all = 0; Not relevant = 0; No \[in question 7.a\] = 0; Question unanswered = 0), resulting in a maximum of 30 and a minimum of 0. The higher the score, the more the quality of life was impaired. A score higher than 10 indicated that the participant's life was being severely affected by their skin disease.

Time frame:
Week 12, Weeks 24 and 40
Reported as:
Mean · units on a scale
Change From Week 12 in the Overall DLQI Score at Weeks 24 and 40
units on a scaleTransition Period: TEV-45779/TEV-45779 High DoseTransition Period: TEV-45779/TEV-45779 Low DoseTransition Period: XOLAIR/XOLAIR High DoseTransition Period: XOLAIR/XOLAIR Low DoseTransition Period: XOLAIR/TEV-45779 High DoseTransition Period: XOLAIR/TEV-45779 Low Dose
Change at Week 24-1.44 ± 3.621-0.43 ± 5.619-1.19 ± 4.387-1.82 ± 5.552-0.88 ± 4.788-1.60 ± 4.271
Change at Week 401.65 ± 7.5811.05 ± 7.5450.51 ± 7.0960.39 ± 5.0982.45 ± 7.7911.10 ± 7.570
SecondaryNumber of Participants With at Least One Treatment-emergent Adverse Event (TEAE) in the Main Treatment Period

An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious AEs (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. AEs were considered TEAEs if onset occurred or worsened on or after the first dose date. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) in the Main Treatment Period
ParticipantsMain Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low Dose
Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) in the Main Treatment Period64377133
SecondaryNumber of Participants With at Least One TEAE Week 12 up to Week 24

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. AEs were considered TEAEs if onset occurred or worsened on or after the first dose date. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Week 12 up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With at Least One TEAE Week 12 up to Week 24
ParticipantsTransition Period: TEV-45779/TEV-45779 High DoseTransition Period: TEV-45779/TEV-45779 Low DoseTransition Period: XOLAIR/XOLAIR High DoseTransition Period: XOLAIR/XOLAIR Low DoseTransition Period: XOLAIR/TEV-45779 High DoseTransition Period: XOLAIR/TEV-45779 Low Dose
Number of Participants With at Least One TEAE Week 12 up to Week 24783443183816
SecondaryNumber of Participants With Antidrug Antibodies (ADAs) in the Main Treatment Period

Number of participants with positive ADA, positive ADA not treatment-related, and negative ADA are reported.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Antidrug Antibodies (ADAs) in the Main Treatment Period
ParticipantsMain Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low Dose
Positive1863713
Positive, Not Treatment Related8554
Negative1739015985
SecondaryNumber of Participants With ADAs From Week 12 to Week 24

Number of participants with positive ADA, positive ADA not treatment-related, and negative ADA are reported.

Time frame:
Week 12 up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With ADAs From Week 12 to Week 24
ParticipantsTransition Period: TEV-45779/TEV-45779 High DoseTransition Period: TEV-45779/TEV-45779 Low DoseTransition Period: XOLAIR/XOLAIR High DoseTransition Period: XOLAIR/XOLAIR Low DoseTransition Period: XOLAIR/TEV-45779 High DoseTransition Period: XOLAIR/TEV-45779 Low Dose
Positive3415104148
Positive, Not Treatment Related643112
Negative1427683458138

Adverse events

Collected over Baseline up to Week 40. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Treatment Period: TEV-45779 High Dose0/201 (0%)1/201 (0.5%)30/201 (14.9%)
Main Treatment Period: TEV-45779 Low Dose0/102 (0%)0/102 (0%)19/102 (18.6%)
Main Treatment Period: XOLAIR High Dose0/203 (0%)3/203 (1.5%)30/203 (14.8%)
Main Treatment Period: XOLAIR Low Dose0/102 (0%)0/102 (0%)10/102 (9.8%)
Transition Period: TEV-45779/TEV-45779 High Dose0/188 (0%)4/188 (2.1%)29/188 (15.4%)
Transition Period: TEV-45779/TEV-45779 Low Dose0/98 (0%)3/98 (3.1%)11/98 (11.2%)
Transition Period: XOLAIR/XOLAIR High Dose0/97 (0%)4/97 (4.1%)16/97 (16.5%)
Transition Period: XOLAIR/XOLAIR Low Dose0/51 (0%)0/51 (0%)8/51 (15.7%)
Transition Period: XOLAIR/TEV-45779 High Dose0/97 (0%)1/97 (1%)10/97 (10.3%)
Transition Period: XOLAIR/TEV-45779 Low Dose0/50 (0%)1/50 (2%)6/50 (12%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventMain Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low DoseTransition Period: TEV-45779/TEV-45779 High DoseTransition Period: TEV-45779/TEV-45779 Low DoseTransition Period: XOLAIR/XOLAIR High DoseTransition Period: XOLAIR/XOLAIR Low DoseTransition Period: XOLAIR/TEV-45779 High DoseTransition Period: XOLAIR/TEV-45779 Low Dose
ColitisGastrointestinal disorders0/2010/1020/2030/1020/1880/980/970/510/971/50
EpiglottitisInfections and infestations0/2010/1020/2030/1020/1880/981/970/510/970/50
Pyelonephritis chronicInfections and infestations0/2010/1020/2030/1020/1880/981/970/510/970/50
Lower limb fractureInjury, poisoning and procedural complications0/2010/1020/2030/1020/1880/980/970/511/970/50
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders0/2010/1020/2030/1020/1880/981/970/510/970/50
UrticariaSkin and subcutaneous tissue disorders0/2010/1020/2030/1021/1881/981/970/510/970/50
Urinary tract infectionInfections and infestations0/2010/1020/2030/1020/1881/980/970/510/970/50
Back painMusculoskeletal and connective tissue disorders0/2010/1020/2030/1020/1881/980/970/510/970/50
CholelithiasisHepatobiliary disorders0/2010/1021/2030/1021/1880/980/970/510/970/50
ErysipelasInfections and infestations0/2010/1020/2030/1021/1880/980/970/510/970/50
Most frequent other events
Most frequent other events
EventMain Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low DoseTransition Period: TEV-45779/TEV-45779 High DoseTransition Period: TEV-45779/TEV-45779 Low DoseTransition Period: XOLAIR/XOLAIR High DoseTransition Period: XOLAIR/XOLAIR Low DoseTransition Period: XOLAIR/TEV-45779 High DoseTransition Period: XOLAIR/TEV-45779 Low Dose
Injection site erythemaGeneral disorders15/20110/10213/2037/1028/1885/983/972/516/973/50
Injection site painGeneral disorders13/2019/10211/2035/1028/1883/982/972/511/972/50
COVID-19Infections and infestations5/2015/1028/2030/1029/1885/987/973/511/972/50
Injection site indurationGeneral disorders12/2016/10212/2035/1027/1883/983/971/513/973/50
Injection site swellingGeneral disorders9/2014/1024/2033/1026/1881/983/970/510/973/50
Upper respiratory tract infectionInfections and infestations5/2013/1022/2030/1029/1881/985/972/511/971/50

Baseline characteristics

The intent-to-treat (ITT) analysis set included all randomized participants.

Age, Continuous
Age, Continuous(years)Main Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low DoseTotal
Mean41.1 ± 14.3042.7 ± 13.6442.0 ± 13.7541.5 ± 14.2941.7 ± 13.99
Sex: Female, Male
Sex: Female, Male(Participants)Main Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low DoseTotal
Female1326913867406
Male69336535202
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Main Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low DoseTotal
Hispanic or Latino4513261195
Not Hispanic or Latino1538817489504
Unknown or Not Reported31329
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Main Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low DoseTotal
Race — American Indian/Alaskan/Native American1244020
Race — Asian65357538213
Race — Black/African American03205
Race — White1235911861361
Race — Other/Mixed10326
Race — Not Reported/Unknown01113
Weekly Itch Severity Score (ISS7)
Weekly Itch Severity Score (ISS7)(units on a scale)Main Treatment Period: TEV-45779 High DoseMain Treatment Period: TEV-45779 Low DoseMain Treatment Period: XOLAIR High DoseMain Treatment Period: XOLAIR Low DoseTotal
Mean16.26 ± 3.72116.14 ± 3.36116.28 ± 3.52416.00 ± 3.72316.20 ± 3.590
08

Study locations

9 sites
  • 10008
    Bakersfield, California 93301, United States
  • Site 10001
    Clearwater, Florida 33765, United States
  • 10012
    Coral Gables, Florida 33134, United States
  • 10006
    Kissimmee, Florida 34744, United States
  • 10014
    Maitland, Florida 32751, United States
  • 10005
    Miami, Florida 33014, United States
  • 10009
    Tampa, Florida 33613, United States
  • 10007
    Troy, Michigan 48084, United States
  • 10004
    Salt Lake City, Utah 84117, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Apr 2024, 31 months.

Results were first posted in Oct 2025, 1 year 6 months after primary completion.

Of 27 industry-sponsored phase 3 interventional studies under Chronic Urticaria, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 31. This study's 31 months is above that.

Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 19 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2021
First posted
Jul 26, 2021
StartActual
Aug 30, 2021
Primary completionActual
Apr 5, 2024
CompletionActual
Apr 5, 2024
Results first posted
Oct 7, 2025
Last update
Oct 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04976192
Collaborators
Teva Pharmaceuticals Development, Inc.
Responsible party
Sponsor
First posted
Jul 26, 2021
Start date
Aug 30, 2021
Primary completion
Apr 5, 2024
Completion
Apr 5, 2024
Results posted
Oct 7, 2025
Last update
Oct 7, 2025

Study contacts

Teva Medical Expert, MD
study director · Teva Pharmaceuticals Development, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion